{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:28:59Z","timestamp":1794018539129,"version":"4.8.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"DOI":"10.1182\/bloodadvances.2023011659","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:39:49Z","timestamp":1704818389000},"page":"248-250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Shrinking the divide: improving myeloma CART access"],"prefix":"10.1182","volume":"8","author":[{"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-0061","authenticated-orcid":false,"given":"Monique A.","family":"Hartley-Brown","sequence":"additional","affiliation":[{"name":"2Multiple Myeloma Program, Dana-Farber\/Harvard Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Multiple Myeloma Program, Dana-Farber\/Harvard Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024010916393182900_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres","year":"2024","journal-title":"Blood Adv"},{"issue":"21","key":"2024010916393182900_bib1","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V122.21.2917.2917","article-title":"Ethnic disparities and their association with outcomes in chronic myeloid leukemia","volume":"122","author":"Ailawadhi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2024010916393182900_bib2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"2024010916393182900_bib3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2024010916393182900_bib4","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2024010916393182900_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024010916393182900_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2024010916393182900_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024010916393182900_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2024010916393182900_bib9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024010916393182900_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2024010916393182900_bib11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2024010916393182900_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024010916393182900_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024010916393182900_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-022-00653-1","article-title":"Daratumumab plus lenalidomide\/bortezomib\/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN","volume":"12","author":"Nooka","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024010916393182900_bib16","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2024010916393182900_bib17","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024010916393182900_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","article-title":"Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare","volume":"2","author":"Gormley","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"suppl 16","key":"2024010916393182900_bib19","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"Jco"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/248\/2180543\/blooda_adv-2023-011659-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/248\/2180543\/blooda_adv-2023-011659-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:38:29Z","timestamp":1731008309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/248\/507003\/Shrinking-the-divide-improving-myeloma-CART-access"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011659","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}